BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Salhy M, Solomon T, Hausken T, Gilja OH, Hatlebakk JG. Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease. World J Gastroenterol 2017; 23(28): 5068-5085 [PMID: 28811704 DOI: 10.3748/wjg.v23.i28.5068] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Aggarwal S, Ranjha R, Paul J. Neuroimmunomodulation by gut bacteria: Focus on inflammatory bowel diseases. World J Gastrointest Pathophysiol 2021; 12(3): 25-39 [PMID: 34084590 DOI: 10.4291/wjgp.v12.i3.25] [Reference Citation Analysis]
2 Terry NA, Ngaba LV, Wilkins BJ, Pi D, Gheewala N, Kaestner KH. Lipid malabsorption from altered hormonal signaling changes early gut microbial responses. Am J Physiol Gastrointest Liver Physiol 2018;315:G580-91. [PMID: 29953253 DOI: 10.1152/ajpgi.00135.2018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 El-Salhy M, Patcharatrakul T, Gonlachanvit S. Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century. World J Gastroenterol 2021; 27(22): 2921-2943 [PMID: 34168399 DOI: 10.3748/wjg.v27.i22.2921] [Reference Citation Analysis]
4 Wu H, Wei J, Wang K, Qi Y, Wang F. Mucus protectors: Promising therapeutic strategies for inflammatory bowel disease. Medical Hypotheses 2018;120:55-9. [DOI: 10.1016/j.mehy.2018.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Puzan M, Hosic S, Ghio C, Koppes A. Enteric Nervous System Regulation of Intestinal Stem Cell Differentiation and Epithelial Monolayer Function. Sci Rep. 2018;8:6313. [PMID: 29679034 DOI: 10.1038/s41598-018-24768-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
6 Li Y, Li X, Geng C, Guo Y, Wang C. Somatostatin receptor 5 is critical for protecting intestinal barrier function in vivo and in vitro. Mol Cell Endocrinol 2021;535:111390. [PMID: 34224803 DOI: 10.1016/j.mce.2021.111390] [Reference Citation Analysis]
7 Wang M, Zhong D, Dong P, Song Y. Blocking CXCR1/2 contributes to amelioration of lipopolysaccharide-induced sepsis by downregulating substance P. J Cell Biochem 2018. [PMID: 30160797 DOI: 10.1002/jcb.27507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Barnig C, Bezema T, Calder PC, Charloux A, Frossard N, Garssen J, Haworth O, Dilevskaya K, Levi-Schaffer F, Lonsdorfer E, Wauben M, Kraneveld AD, Te Velde AA. Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease. Front Immunol 2019;10:1699. [PMID: 31396220 DOI: 10.3389/fimmu.2019.01699] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
9 Sun X, Huang Y, Zhang YL, Qiao D, Dai YC. Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells. World J Gastroenterol 2020; 26(48): 7593-7602 [PMID: 33505138 DOI: 10.3748/wjg.v26.i48.7593] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kasprzak A. Somatostatin and Its Receptor System in Colorectal Cancer. Biomedicines 2021;9:1743. [PMID: 34829972 DOI: 10.3390/biomedicines9111743] [Reference Citation Analysis]
11 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
12 Chen Y, Mu J, Zhu M, Mukherjee A, Zhang H. Transient Receptor Potential Channels and Inflammatory Bowel Disease. Front Immunol 2020;11:180. [PMID: 32153564 DOI: 10.3389/fimmu.2020.00180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Godlewski J, Kmiec Z. Colorectal Cancer Invasion and Atrophy of the Enteric Nervous System: Potential Feedback and Impact on Cancer Progression. Int J Mol Sci 2020;21:E3391. [PMID: 32403316 DOI: 10.3390/ijms21093391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Bains M, Laney C, Wolfe AE, Orr M, Waschek JA, Ericsson AC, Dorsam GP. Vasoactive Intestinal Peptide Deficiency Is Associated With Altered Gut Microbiota Communities in Male and Female C57BL/6 Mice. Front Microbiol 2019;10:2689. [PMID: 31849864 DOI: 10.3389/fmicb.2019.02689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Zhang Y, Zhang H, Zhang K, Li Z, Guo T, Wu T, Hou X, Feng N. Co-hybridized composite nanovesicles for enhanced transdermal eugenol and cinnamaldehyde delivery and their potential efficacy in ulcerative colitis. Nanomedicine 2020;28:102212. [PMID: 32334099 DOI: 10.1016/j.nano.2020.102212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zaher S. Nutrition and the gut microbiome during critical illness: A new insight of nutritional therapy. Saudi J Gastroenterol 2020. [PMID: 33208559 DOI: 10.4103/sjg.SJG_352_20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Koo A, Fothergill LJ, Kuramoto H, Furness JB. 5-HT containing enteroendocrine cells characterised by morphologies, patterns of hormone co-expression, and relationships with nerve fibres in the mouse gastrointestinal tract. Histochem Cell Biol 2021;155:623-36. [PMID: 33608804 DOI: 10.1007/s00418-021-01972-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2018;12:439-445. [PMID: 29493330 DOI: 10.1080/17474124.2018.1447380] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
19 El-Salhy M, Hatlebakk JG, Hausken T. Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides. 2020;79:101973. [PMID: 31727345 DOI: 10.1016/j.npep.2019.101973] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]